BEVESPI Aerosphere - 9mcg/4.8mcg, 120 MDI - Inhaler

BEVESPI AEROSPHERE is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Note: This is the EU Brand Name BEVESPI Aerosphere inhaler that delivers 9 mcg of glycopyrrolate and 4.8 mcg of formoterol fumarate (equivalent to 7.2mcg/5 mcg) from the actuator.